Drug Trial Radar · NCT00355134
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Aug 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,083
Actual
Start
Jun 2006
Primary completion
Jun 2011
Study completion Aug 2011
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 21, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study assessed the safety, tolerability and efficacy of two doses of oral fingolimod compared to placebo on efficacy parameters in patients with relapsing-remitting multiple sclerosis (RRMS).
Conditions
- Multiple Sclerosis
Interventions
FingolimodDrug
Fingolimod capsules for oral administration
PlaceboDrug
Matching placebo capsules for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Aggregate Annualized Relapse Rate (ARR) Estimate up to Month 24Time frame: 24 months
Locations
112 sites in 8 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama
North Central Neurology Associates, PC
Cullman, Alabama
University of South Alabama - Dept of Neurology
Mobile, Alabama
Barrow Neurology Clinic
Phoenix, Arizona
Research and Education Institute of Alta Bates Summit Medical Center
Berkeley, California
University of California - Irvine, Deptarment of Neurology
Irvine, California
Cedars Sinai Medical Center
Los Angeles, California
The Neurology Center
Oceanside, California
Neuro-Therapeutics, Inc.
Pasadena, California
UC Davis Medical Center
Sacramento, California
Multiple Sclerosis Center at UCSF
San Francisco, California
University of Colorado
Denver, Colorado
Associated Neurologists, PC
Danbury, Connecticut
Associated Neurologists of Southern CT, P.C.
Fairfield, Connecticut
Yale University - Yale Multiple Sclerosis Center
New Haven, Connecticut
Georgetown University Hospital - Dept of Neurology
Washington D.C., District of Columbia
Sunrise Clinical Research, Inc.
Hollywood, Florida
University of Florida Health Sciences Center/Shands Jacksonville
Jacksonville, Florida
Neurology Associates, PA
Maitland, Florida
University of Miami, Department of Neurology
Miami, Florida
Neurological Associates
Pompano Beach, Florida
Roskamp Institute, Clinical Trials Division
Sarasota, Florida
Neurology Clinical Research, Inc
Sunrise, Florida
AMO Corporation
Tallahassee, Florida
Axiom Clinical Research of Florida
Tampa, Florida
The MS Center of Vero Beach
Vero Beach, Florida
MS Center of Atlanta
Atlanta, Georgia
Medical College of Georgia
Augusta, Georgia
Northwestern University Medical School - Dept of Neurology
Chicago, Illinois
Rush University Medical Center Department of Neurological Sciences
Chicago, Illinois
University of Chicago - Dept of Neurology
Chicago, Illinois
Alexian Brothers Neurosciences Research
Elk Grove Village, Illinois
South Suburban Neurology
Flossmoor, Illinois
Neurologic Associates, Ltd.
Palos Heights, Illinois
Fort Wayne Neurological Center
Fort Wayne, Indiana
Indiana University Medical Center
Indianapolis, Indiana
Ruan Neurology Clinical Research Center
Des Moines, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Mid America Neuroscience Institute
Lenexa, Kansas
Kentucky Research Associates
Louisville, Kentucky
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.